Literature DB >> 1310199

Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes.

D M Margolis1, A B Rabson, S E Straus, J M Ostrove.   

Abstract

Herpes simplex virus type 1 (HSV-1) activates transcription from the long terminal repeat (LTR) promoter region of the human immunodeficiency virus type 1 (HIV-1). HSV-1 immediate-early (IE) genes ICP0 and ICP4 are thought to be important mediators of this process, which is known to involve the induction of the cellular activators NF-kappa B and Sp1. We demonstrate that ICP0 and ICP4 transactivation of the LTR is largely dependent on the presence of NF-kappa B and Sp1 binding sites. However, in Jurkat CD4-positive lymphocytes, HSV-1 activates LTR constructs lacking all NF-kappa B or Sp1 Binding sequences. This effect is still evident when all sequences upstream of the TATA motif are removed. Such enhancer-independent transactivation can be produced by cotransfection of ICP0 and ICP4. Thus HSV-1 IE genes transactivate the HIV-1 LTR both through the induction of NF-kappa B and Sp1 and through another as yet undefined cellular factor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310199     DOI: 10.1016/0042-6822(92)90048-t

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  27 in total

1.  c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter.

Authors:  Guochun Jiang; Amy Espeseth; Daria J Hazuda; David M Margolis
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

2.  Cervico-vaginal tissue ex vivo as a model to study early events in HIV-1 infection.

Authors:  Melanie Merbah; Andrea Introini; Wendy Fitzgerald; Jean-Charles Grivel; Andrea Lisco; Christophe Vanpouille; Leonid Margolis
Journal:  Am J Reprod Immunol       Date:  2011-01-12       Impact factor: 3.886

3.  Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses.

Authors:  C M Posavad; D M Koelle; M F Shaughnessy; L Corey
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

4.  Mechanisms of viral infections associated with HIV: workshop 2B.

Authors:  S M Tugizov; J Y Webster-Cyriaque; S Syrianen; A Chattopadyay; H Sroussi; L Zhang; A Kaushal
Journal:  Adv Dent Res       Date:  2011-04

Review 5.  The Sordid Affair Between Human Herpesvirus and HIV.

Authors:  Sara Gianella; Marta Massanella; Joel O Wertheim; Davey M Smith
Journal:  J Infect Dis       Date:  2015-03-06       Impact factor: 5.226

6.  New insights on interactions between HIV-1 and HSV-2.

Authors:  Sinéad Delany-Moretlwe; Jairam R Lingappa; Connie Celum
Journal:  Curr Infect Dis Rep       Date:  2009-03       Impact factor: 3.725

7.  The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation.

Authors:  Moira A McMahon; Janet D Siliciano; Jun Lai; Jun O Liu; James T Stivers; Robert F Siliciano; Rahul M Kohli
Journal:  J Biol Chem       Date:  2008-09-24       Impact factor: 5.157

8.  Synergistic activation of simian immunodeficiency virus and human immunodeficiency virus type 1 transcription by retinoic acid and phorbol ester through an NF-kappa B-independent mechanism.

Authors:  J W Maciaszek; D A Talmage; G A Viglianti
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

Review 9.  NF-kappaB and virus infection: who controls whom.

Authors:  M Gabriella Santoro; Antonio Rossi; Carla Amici
Journal:  EMBO J       Date:  2003-06-02       Impact factor: 11.598

10.  Cells lacking NF-kappaB or in which NF-kappaB is not activated vary with respect to ability to sustain herpes simplex virus 1 replication and are not susceptible to apoptosis induced by a replication-incompetent mutant virus.

Authors:  Brunella Taddeo; Weiran Zhang; Fred Lakeman; Bernard Roizman
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.